D'Annunzio University of Chieti–Pescara   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Chieti Italy (1960)

Organization Overview

First Clinical Trial
2003
NCT00565500
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Centro dell'invecchiamento, Chieti | Diabetology Dept Univ of Chieti | G. d'Annunzio University | Institute of Cardiology, G. d'Annunzio University | Institute of Cardiology - G. d'Annunzio University, Chieti | Institute of Nephrology, G. D'annunzio University, Chieti, Italy | Institute of Nephrology, University of Chieti, Italy | ObGyn Dept University of Chieti | ObGyn Dept Univ of Chieti | Raffaele De Caterina | Università degli Studi G. d'Annunzio Chieti | Università degli Studi 'G. d'Annunzio' Chieti e Pescara | University of Chieti

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Arteriosclerosis (Phase 2)

Atrial Fibrillation (Phase 2)

Cataract (Phase 4)

Colorectal Neoplasms (Phase 3)

Coronary Artery Disease (Phase 4)

Eye Infections (Phase 4)

Glomerulonephritis (Phase 3)

Glomerulonephritis, Membranous (Phase 3)

Heart Diseases (Phase 4)

Infertility (Phase 4)

Inflammation (Phase 3)

Insulin Resistance (Phase 2)

Kidney Failure, Chronic (Phase 2)

Myocardial Ischemia (Phase 4)

Nausea (Phase 4)

Parkinson Disease (Phase 3)

Thrombocytopenia (Phase 4)

Thromboembolism (Phase 4)

Thrombosis (Phase 2)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial APIs: 31